Washington State University to review claims of research misconduct
Washington State University has initiated a review of potential research misconduct claims involving former student Leen Kawas, now the CEO of Athira Pharma (NASDAQ: ATHA).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Washington State University has initiated a review of potential research misconduct claims involving former student Leen Kawas, now the CEO of Athira Pharma (NASDAQ: ATHA). The Athira board has placed Kawas on temporary leave while it conducts its own investigation into her doctoral research. WSU emphasizes its commitment to high ethical standards in research and is adhering to its Executive Policy 33 for handling such allegations. Further details will be withheld until the review is concluded.
Positive
- Athira Pharma is taking proactive measures by placing CEO Leen Kawas on leave to address the allegations.
Negative
- The investigation into research misconduct could harm Athira's reputation and investor confidence.
- Uncertainty regarding the outcome of the investigation may lead to stock volatility.
Details
News Market Reaction – ATHA
The recorded move for ATHA in the trading session of this news was -38.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PULLMAN, Wash., June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by Leen Kawas, a former WSU student and current president and chief executive officer of Athira Pharma, Inc. (NASDAQ: ATHA). On Thursday, the Athira Pharma board of directors announced that it had placed Kawas on temporary leave pending its own review of actions stemming from Kawas' doctoral research while at WSU.
Washington State University expects its researchers to adhere to the highest ethical standards in the conduct of research activities. The University takes allegations of research misconduct very seriously. WSU is conducting its inquiry into this issue in accordance with the University's Executive Policy 33, which governs how the institution responds to allegations of research misconduct.
Washington State University will refrain from discussing the matter further until the review process is complete.
View original content:http://www.prnewswire.com/news-releases/washington-state-university-to-review-claims-of-research-misconduct-301315597.html
SOURCE Washington State University
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.